In a nutshell This study aimed to investigate the safety and effectiveness of different chemotherapy and targeted therapy combinations given as frontline treatment in patients with chronic lymphocytic leukemia in a real-world setting. This study concluded that some treatments have a real-world activity that is comparable to clinical trial...
Read More
In a nutshell This study aimed to investigate the impact of maintenance treatment on cancer-related fatigue and sleep-wake rhythms in pediatric patients with acute lymphoblastic leukemia. This study concluded that sleep-wake rhythms are disturbed, physical activity levels lower and cancer-related fatigue levels higher...
Read MoreIn a nutshell The study evaluated the long-term effectiveness and safety of Ofatumumab (Arzerra) and chlorambucil (Leukeran) (CHL) in patients with previously untreated chronic lymphocytic leukemia (CLL). The authors found that the combination therapy safely improved clinical outcomes in such patients in 5 years, compared to chlorambucil alone. Some...
Read More
In a nutshell The study evaluated the effectiveness and safety of imatinib (Gleevec) in treating children and adolescents with chronic myeloid leukemia (CML). The main finding was that imatinib was effective against CML and safe in this patient population. Some background Imatinib deactivates a cancerous enzyme called BCR-ABL1. Lately, imatinib...
Read MoreIn a nutshell This study aimed to investigate the outcomes for patients with newly diagnosed acute lymphoblastic leukemia who were treated liposomal vincristine and chemotherapy. This study concluded that this combination was safe and effective in these patients. Some background Liposomal vincristine (Marqibo) is a...
Read MoreIn a nutshell The study compared the effects of single and multi-agent chemotherapies on survival in older patients with newly diagnosed acute myeloid leukemia (AML) in a real-world setting. The main finding was that chemotherapy with multiple drugs improved survival in such patients, compared to single-agent therapy. Some background Older patients...
Read MoreIn a nutshell The study evaluated the effectiveness of two salvage therapies – mitoxantrone (Novantrone), etoposide (Etopophos), and cytarabine (Cytosar-U) also known as MEC and cladribine (Leustatin), cytarabine, filgrastim (Neupogen), and mitoxantrone also known as CLAG-M, for treating relapsed/refractory acute myeloid leukemia...
Read MoreIn a nutshell The study investigated the effects of switching treatment to nilotinib (Tasigna) after initial therapy with imatinib (Gleevec) in patients with chronic phase of chronic myeloid leukemia (CP-CML). The authors found that switching to nilotinib after imatinib initial treatment is convenient and effective in such patients. Some background...
Read MoreIn a nutshell This study investigated preimplantation genetic testing for aneuploidy (PGT-A) for fertility preservation (FP). They found that PGT-A was useful in cancer patients attempting FP. Some background Assisted reproductive technology (ART) is used to treat infertility. It is also an important option for cancer patients. Cancer...
Read More
In a nutshell This study aimed to investigate the addition of cladribine to standard induction chemotherapy in patients with acute myeloid leukemia. This study concluded that the patients treated with added cladribine had better outcomes when compared to patients who received standard induction chemotherapy...
Read More
In a nutshell This study investigated if a higher dose of PEG-asparaginase (Oncaspar) with early induction and additional triple intrathecal therapy (TIT) can prevent relapse in the brain in children with acute lymphoblastic leukemia (ALL). The authors found that additional TIT during early induction improved the outcomes of these...
Read MoreIn a nutshell This study aimed to compare the effectiveness of new-generation tyrosine kinase inhibitors and imatinib in patients with newly diagnosed chronic myeloid leukemia. This study concluded that for first-line treatment, new-generation tyrosine kinase inhibitors are better than imatinib. Some background Tyrosine...
Read More
